Published in Biochemistry on February 01, 2000
Designed tumor necrosis factor-related apoptosis-inducing ligand variants initiating apoptosis exclusively via the DR5 receptor. Proc Natl Acad Sci U S A (2006) 1.45
The methionine-aromatic motif plays a unique role in stabilizing protein structure. J Biol Chem (2012) 1.28
Death receptors as targets in cancer. Br J Pharmacol (2013) 1.24
RNA aptamers selected against the receptor activator of NF-kappaB acquire general affinity to proteins of the tumor necrosis factor receptor family. Nucleic Acids Res (2004) 1.12
Decoy strategies: the structure of TL1A:DcR3 complex. Structure (2011) 1.10
Irradiation specifically sensitises solid tumour cell lines to TRAIL mediated apoptosis. BMC Cancer (2005) 1.08
RANKL employs distinct binding modes to engage RANK and the osteoprotegerin decoy receptor. Structure (2012) 1.04
EDA gene mutations underlie non-syndromic oligodontia. J Dent Res (2009) 1.02
Zinc-binding cysteines: diverse functions and structural motifs. Biomolecules (2014) 1.00
Desiccation and zinc binding induce transition of tomato abscisic acid stress ripening 1, a water stress- and salt stress-regulated plant-specific protein, from unfolded to folded state. Plant Physiol (2006) 0.94
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induces death receptor 5 networks that are highly organized. J Biol Chem (2012) 0.93
Possible novel therapy for malignant gliomas with secretable trimeric TRAIL. PLoS One (2009) 0.92
Biochemical and structural characterization of the human TL1A ectodomain. Biochemistry (2009) 0.92
Unraveling the binding mechanism of trivalent tumor necrosis factor ligands and their receptors. Mol Cell Proteomics (2010) 0.90
Onto better TRAILs for cancer treatment. Cell Death Differ (2016) 0.88
In-silico prediction of disorder content using hybrid sequence representation. BMC Bioinformatics (2011) 0.87
Principles of antibody-mediated TNF receptor activation. Cell Death Differ (2015) 0.84
Binding Studies of TNF Receptor Superfamily (TNFRSF) Receptors on Intact Cells. J Biol Chem (2015) 0.80
Isolation of a TRAIL antagonist from the serum of HIV-infected patients. J Biol Chem (2011) 0.80
Signaling through C/EBP homologous protein and death receptor 5 and calpain activation differentially regulate THP-1 cell maturation-dependent apoptosis induced by Shiga toxin type 1. Infect Immun (2010) 0.79
The role of tumor necrosis factor receptor superfamily members in mammalian brain development, function and homeostasis. Rev Neurosci (2011) 0.79
Cloning and Expression of TNF Related Apoptosis Inducing Ligand in Nicotiana tabacum. Iran J Pharm Res (2015) 0.78
The structure of the death receptor 4-TNF-related apoptosis-inducing ligand (DR4-TRAIL) complex. Acta Crystallogr F Struct Biol Commun (2015) 0.78
Intracellular localization of DR5 and related regulatory pathways as a mechanism of resistance to TRAIL in cancer. Cell Mol Life Sci (2016) 0.78
Combination of TRAIL with bortezomib shifted apoptotic signaling from DR4 to DR5 death receptor by selective internalization and degradation of DR4. PLoS One (2014) 0.77
Structural Insight for Roles of DR5 Death Domain Mutations on Oligomerization of DR5 Death Domain-FADD Complex in the Death-Inducing Signaling Complex Formation: A Computational Study. J Mol Model (2016) 0.77
TNF superfamily protein-protein interactions: feasibility of small- molecule modulation. Curr Drug Targets (2015) 0.77
DR4 specific TRAIL variants are more efficacious than wild-type TRAIL in pancreatic cancer. Cancer Biol Ther (2014) 0.77
An optimized antibody-single-chain TRAIL fusion protein for cancer therapy. MAbs (2016) 0.77
The Biology of TRAIL and the Role of TRAIL-Based Therapeutics in Infectious Diseases. Antiinfect Agents Med Chem (2009) 0.77
Annexin V-TRAIL fusion protein is a more sensitive and potent apoptotic inducer for cancer therapy. Sci Rep (2013) 0.76
Piecing it together: Unraveling the elusive structure-function relationship in single-pass membrane receptors. Biochim Biophys Acta (2017) 0.76
Antitherapeutic antibody-mediated hepatotoxicity of recombinant human Apo2L/TRAIL in the cynomolgus monkey. Cell Death Dis (2016) 0.75
TRAIL-receptor 1 IgM antibodies strongly induce apoptosis in human cancer cells in vitro and in vivo. Oncoimmunology (2016) 0.75
Whole genome sequencing reveals novel non-synonymous mutation in ectodysplasin A (EDA) associated with non-syndromic X-linked dominant congenital tooth agenesis. PLoS One (2014) 0.75
Death Receptor 5 Activation Is Energetically Coupled to Opening of the Transmembrane Domain Dimer. Biophys J (2017) 0.75
Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science (1997) 6.82
Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem (1996) 6.22
Convergent solutions to binding at a protein-protein interface. Science (2000) 4.47
Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ (2003) 3.66
Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. Immunity (2000) 3.45
Primary structure and biochemical properties of an M2 muscarinic receptor. Science (1987) 3.16
Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. Nature (1998) 2.98
Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen. J Mol Biol (1999) 2.85
IL-17s adopt a cystine knot fold: structure and activity of a novel cytokine, IL-17F, and implications for receptor binding. EMBO J (2001) 2.84
Identification of a receptor for BLyS demonstrates a crucial role in humoral immunity. Nat Immunol (2000) 2.78
Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. Nat Med (2001) 2.66
New insights into apoptosis signaling by Apo2L/TRAIL. Oncogene (2010) 2.56
Triggering cell death: the crystal structure of Apo2L/TRAIL in a complex with death receptor 5. Mol Cell (1999) 2.42
Death receptor recruitment of endogenous caspase-10 and apoptosis initiation in the absence of caspase-8. J Biol Chem (2001) 2.40
Distinct primary structures, ligand-binding properties and tissue-specific expression of four human muscarinic acetylcholine receptors. EMBO J (1987) 2.39
An analysis of closed obstetric malpractice claims. Obstet Gynecol (1989) 2.34
Herpesvirus entry mediator, a member of the tumor necrosis factor receptor (TNFR) family, interacts with members of the TNFR-associated factor family and activates the transcription factors NF-kappaB and AP-1. J Biol Chem (1997) 2.33
A novel receptor for Apo2L/TRAIL contains a truncated death domain. Curr Biol (1997) 2.31
Interaction of the TNF homologues BLyS and APRIL with the TNF receptor homologues BCMA and TACI. Curr Biol (2000) 2.29
Bacterial injury: a review. Can J Microbiol (1977) 2.26
Mapping of the C1q binding site on rituxan, a chimeric antibody with a human IgG1 Fc. J Immunol (2000) 2.25
Crystal structure at 1.7 A resolution of VEGF in complex with domain 2 of the Flt-1 receptor. Cell (1997) 2.24
Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety. J Pharmacol Exp Ther (2001) 2.13
Differential regulation of PI hydrolysis and adenylyl cyclase by muscarinic receptor subtypes. Nature (1988) 2.03
VEGF and the Fab fragment of a humanized neutralizing antibody: crystal structure of the complex at 2.4 A resolution and mutational analysis of the interface. Structure (1998) 2.02
Two-amino acid molecular switch in an epithelial morphogen that regulates binding to two distinct receptors. Science (2000) 1.95
TACI-ligand interactions are required for T cell activation and collagen-induced arthritis in mice. Nat Immunol (2001) 1.92
Vascular endothelial growth factor: crystal structure and functional mapping of the kinase domain receptor binding site. Proc Natl Acad Sci U S A (1997) 1.91
Ligand-induced autoregulation of IFN-gamma receptor beta chain expression in T helper cell subsets. Science (1995) 1.90
Crystal structure of nerve growth factor in complex with the ligand-binding domain of the TrkA receptor. Nature (1999) 1.86
Structural and functional analysis of the 1:1 growth hormone:receptor complex reveals the molecular basis for receptor affinity. J Mol Biol (1998) 1.79
Nisin: its preservative effect and function in the growth cycle of the producer organism. Soc Appl Bacteriol Symp Ser (1978) 1.78
Preparation of spheroplasts from Streptococcus lactis. Can J Microbiol (1972) 1.77
Peptide exosite inhibitors of factor VIIa as anticoagulants. Nature (2000) 1.77
The MHC-binding and gp120-binding functions of CD4 are separable. Science (1989) 1.77
Apo-3, a new member of the tumor necrosis factor receptor family, contains a death domain and activates apoptosis and NF-kappa B. Curr Biol (1996) 1.72
Hematopoietic receptor complexes. Annu Rev Biochem (1996) 1.67
Generation of a humanized, high affinity anti-tissue factor antibody for use as a novel antithrombotic therapeutic. Thromb Haemost (2001) 1.64
Identification of a new member of the tumor necrosis factor family and its receptor, a human ortholog of mouse GITR. Curr Biol (1999) 1.63
Structural and functional analysis of the interaction between the agonistic monoclonal antibody Apomab and the proapoptotic receptor DR5. Cell Death Differ (2008) 1.61
The interaction of neuropilin-1 with vascular endothelial growth factor and its receptor flt-1. J Biol Chem (2000) 1.60
Crystal structures at 2.2 A resolution of the catalytic domains of normal ras protein and an oncogenic mutant complexed with GDP. J Mol Biol (1991) 1.59
Nisin: a possible alternative or adjunct to nitrite in the preservation of meats. Appl Environ Microbiol (1981) 1.58
Soluble decoy receptor 3 is expressed by malignant gliomas and suppresses CD95 ligand-induced apoptosis and chemotaxis. Cancer Res (2001) 1.58
Identification of multiple sources of charge heterogeneity in a recombinant antibody. J Chromatogr B Biomed Sci Appl (2001) 1.57
Targeting FGF19 inhibits tumor growth in colon cancer xenograft and FGF19 transgenic hepatocellular carcinoma models. Oncogene (2007) 1.57
A p55 TNF receptor immunoadhesin prevents T cell-mediated intestinal injury by inhibiting matrix metalloproteinase production. J Immunol (1998) 1.53
Thermodynamic analysis of an antibody functional epitope. Biochemistry (1993) 1.49
Direct selection for curing and deletion of Rhizobium plasmids using transposons carrying the Bacillus subtilis sacB gene. Gene (1989) 1.48
Isotype-dependent inhibition of tumor growth in vivo by monoclonal antibodies to death receptor 4. J Immunol (2001) 1.46
The crystal structure of vascular endothelial growth factor (VEGF) refined to 1.93 A resolution: multiple copy flexibility and receptor binding. Structure (1997) 1.46
The syndrome of neonatal copper deficiency. Pediatrics (1973) 1.45
High level Escherichia coli expression and production of a bivalent humanized antibody fragment. Biotechnology (N Y) (1992) 1.43
Three-dimensional structure of thaumatin I, an intensely sweet protein. Proc Natl Acad Sci U S A (1985) 1.43
Functional characterization of the Bcl-2 gene family in the zebrafish. Cell Death Differ (2006) 1.43
Engineered antibodies with increased activity to recruit complement. J Immunol (2001) 1.40
Pheochromocytoma, sickle cell disease and pregnancy: a case report. J Matern Fetal Neonatal Med (2003) 1.39
Fas antigen signals proliferation of normal human diploid fibroblast and its mechanism is different from tumor necrosis factor receptor. FEBS Lett (1995) 1.37
The Ca2+ ion and membrane binding structure of the Gla domain of Ca-prothrombin fragment 1. Biochemistry (1992) 1.37
X-ray crystal structures of transforming p21 ras mutants suggest a transition-state stabilization mechanism for GTP hydrolysis. Proc Natl Acad Sci U S A (1992) 1.34
Identification of a ligand for the death-domain-containing receptor Apo3. Curr Biol (1998) 1.34
Locoregional Apo2L/TRAIL eradicates intracranial human malignant glioma xenografts in athymic mice in the absence of neurotoxicity. Biochem Biophys Res Commun (1999) 1.33
Activation of apoptosis by Apo-2 ligand is independent of FADD but blocked by CrmA. Curr Biol (1996) 1.33
A common variant of the interleukin 6 receptor (IL-6r) gene increases IL-6r and IL-6 levels, without other inflammatory effects. Genes Immun (2007) 1.33
APO2 ligand: a novel lethal weapon against malignant glioma? FEBS Lett (1998) 1.32
Ligand-induced assembly and activation of the gamma interferon receptor in intact cells. Mol Cell Biol (1996) 1.32
Biosynthesis of the antibiotic nisin by whole Streptococcus lactus organisms. J Gen Microbiol (1966) 1.30
Structure and function of human growth hormone: implications for the hematopoietins. Annu Rev Biophys Biomol Struct (1993) 1.26
A single amino-acid difference confers major pharmacological variation between human and rodent 5-HT1B receptors. Nature (1992) 1.26
Nerve growth factor: structure and function. Cell Mol Life Sci (2001) 1.25
Structure of ras proteins. Science (1989) 1.24
Preparation of a highly active form of nisin from Streptococcus lactis. Can J Microbiol (1971) 1.24
Simple Ulcer of the OEsophagus and Short OEsophagus: (Section of Medicine). Proc R Soc Med (1939) 1.23
Risks of angiotensin-converting enzyme inhibition during pregnancy: experimental and clinical evidence, potential mechanisms, and recommendations for use. Am J Med (1994) 1.23
Crystallization and stoichiometry of binding of a complex between a rat intestinal Fc receptor and Fc. J Mol Biol (1993) 1.22
Structural differences between a ras oncogene protein and the normal protein. Nature (1989) 1.20
Cloning and expression of a human CDC42 GTPase-activating protein reveals a functional SH3-binding domain. J Biol Chem (1993) 1.20
The location of nisin in the producer organism, Streptococcus lactis. J Gen Microbiol (1968) 1.20
Caesarean section controversy. Further research is needed on why rates of caesarean section are increasing. BMJ (2000) 1.19
Loss of D-alanine during sublethal heating of Staphylococcus aureus S6 and magnesium binding during repair. J Gen Microbiol (1975) 1.18
Ligand-binding sites in Ig-like domains of receptor tyrosine kinases. J Mol Med (Berl) (2000) 1.17
Synthesis of enterotoxin B by Staphylococcus aureus strain S6 after recovery from heat injury. Can J Microbiol (1973) 1.17
Iron treatment in children with attention deficit hyperactivity disorder. A preliminary report. Neuropsychobiology (1997) 1.14
Observations on the action of benzylpenicillin on a strain of Streptococcus lactis. J Gen Microbiol (1969) 1.13
The crystal structure of the extracellular domain of human tissue factor refined to 1.7 A resolution. J Mol Biol (1996) 1.13
Mobility-molecular weight relationships of small proteins and peptides in acrylamide-gel electrophoresis. Anal Biochem (1967) 1.13
Crystal structures of the neurotrophin-binding domain of TrkA, TrkB and TrkC. J Mol Biol (1999) 1.13
Solution structure of the E-domain of staphylococcal protein A. Biochemistry (1996) 1.12